Skip to content

Study · Randomized controlled trial · n = 26 · 1995

11 results

Ovulation triggering in clomiphene citrate-stimulated cycles: human chorionic gonadotropin versus a gonadotropin releasing hormone agonist.

Schmidt-Sarosi C, Kaplan DR, Sarosi P, Essig MN, Licciardi FL, Keltz M, Levitz M

Journal of assisted reproduction and genetics1 Mar 1995Cited by 13 (Europe PMC)

PMID8520180 (opens in a new tab)DOI10.1007/bf02211793 (opens in a new tab)PepBankPUB-08520180
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In infertile women primed with clomiphene, an LH surge occurred in all 11 nafarelin patients versus 8 hCG patients (P = 0.01).

    In plain wordsIn infertile women primed with clomiphene, LH surges occurred more often with nafarelin than hCG.

    Peptide
    Nafarelin
    Outcome
    IncreaseLH surge on LD1
    Study

    n = 26

    Comparator
    hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 micrograms per dose · intranasalAs given in this study (human).

    Measurements

    Patients with LH surge on LD1
    11 patients
    nafarelin
    Patients with LH surge on LD1
    8 patients
    hCG
    P value
    0.01
    nafarelin vs hCG

    Source sentences

    Summary
    As judged by a threefold rise in serum LH, an LH surge was detected on LD1 in all 11 nafarelin patients, but in only 8 hCG patients (P = 0.01).
    3 context sentences
    Summary · context
    In 26 infertile women 50 mg clomiphene citrate produced a preovulatory-size follicle.
    Summary · context
    Then, 11 women were randomized to receive two 400-micrograms doses of nafarelin intranasally 16 h apart, and 15 women were injected intramuscularly with 5000 IU of hCG (luteal day 0 = LD0).
    Summary · context
    Starting on LD6, 7 more 400-micrograms doses of nafarelin were repeated on an every 16-h schedule or a single 2500 IU dose of hCG was given, respectively.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In infertile women primed with clomiphene, pregnancy occurred in 3 of 11 nafarelin cycles versus 2 of 15 hCG cycles.

    In plain wordsIn infertile women primed with clomiphene, pregnancy occurred in 3 of 11 nafarelin cycles versus 2 of 15 hCG cycles.

    Peptide
    Nafarelin
    Outcome
    IncreasePregnancy
    Study

    n = 26

    Comparator
    hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 micrograms per dose · intranasalAs given in this study (human).

    Measurements

    Pregnancies
    3 cycles (of 11)
    nafarelin
    Pregnancies
    2 cycles (of 15)
    hCG

    Source sentences

    Summary
    Pregnancies were achieved in 3 of 11 nafarelin cycles and 2 of 15 hCG cycles.
    3 context sentences
    Summary · context
    In 26 infertile women 50 mg clomiphene citrate produced a preovulatory-size follicle.
    Summary · context
    Then, 11 women were randomized to receive two 400-micrograms doses of nafarelin intranasally 16 h apart, and 15 women were injected intramuscularly with 5000 IU of hCG (luteal day 0 = LD0).
    Summary · context
    Starting on LD6, 7 more 400-micrograms doses of nafarelin were repeated on an every 16-h schedule or a single 2500 IU dose of hCG was given, respectively.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In nonpregnant women primed with clomiphene, luteal phase defects were similar: 4 of 8 nafarelin patients versus 7 of 11 hCG patients.

    In plain wordsIn nonpregnant women primed with clomiphene, luteal phase defects were similar with nafarelin and hCG.

    Peptide
    Nafarelin
    Outcome
    DecreaseLuteal phase defects
    Study

    n = 19

    Comparator
    hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 micrograms per dose · intranasalAs given in this study (human).

    Measurements

    Luteal phase defects
    4 patients (of 8)
    nafarelin
    Luteal phase defects
    7 patients (of 11)
    hCG

    Source sentences

    Summary
    Luteal phase defects were also similar: 4 of 8 nafarelin patients and 7 of 11 hCG patients.
    4 context sentences
    Summary · context
    On LD13, endometrium was evaluated with ultrasonography and biopsy in 19 nonpregnant women.
    Summary · context
    In 26 infertile women 50 mg clomiphene citrate produced a preovulatory-size follicle.
    Summary · context
    Then, 11 women were randomized to receive two 400-micrograms doses of nafarelin intranasally 16 h apart, and 15 women were injected intramuscularly with 5000 IU of hCG (luteal day 0 = LD0).
    Summary · context
    Starting on LD6, 7 more 400-micrograms doses of nafarelin were repeated on an every 16-h schedule or a single 2500 IU dose of hCG was given, respectively.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In infertile women primed with clomiphene, LH levels were significantly higher on LD1, 7, and 8 with nafarelin than hCG.

    In plain wordsIn infertile women primed with clomiphene, LH levels were higher on LD1, 7, and 8 with nafarelin than hCG.

    Peptide
    Nafarelin
    Outcome
    IncreaseLH on LD1, 7, and 8
    Study

    n: not reported in source

    Comparator
    hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 micrograms per dose · intranasalAs given in this study (human).

    Source sentences

    Summary
    LH and FSH levels were significantly higher on LD1, 7, and 8 and were significantly suppressed on LD13 in the nafarelin group.
    3 context sentences
    Summary · context
    In 26 infertile women 50 mg clomiphene citrate produced a preovulatory-size follicle.
    Summary · context
    Then, 11 women were randomized to receive two 400-micrograms doses of nafarelin intranasally 16 h apart, and 15 women were injected intramuscularly with 5000 IU of hCG (luteal day 0 = LD0).
    Summary · context
    Starting on LD6, 7 more 400-micrograms doses of nafarelin were repeated on an every 16-h schedule or a single 2500 IU dose of hCG was given, respectively.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In infertile women primed with clomiphene, FSH levels were significantly higher on LD1, 7, and 8 with nafarelin than hCG.

    In plain wordsIn infertile women primed with clomiphene, FSH levels were higher on LD1, 7, and 8 with nafarelin than hCG.

    Peptide
    Nafarelin
    Outcome
    IncreaseFSH on LD1, 7, and 8
    Study

    n: not reported in source

    Comparator
    hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 micrograms per dose · intranasalAs given in this study (human).

    Source sentences

    Summary
    LH and FSH levels were significantly higher on LD1, 7, and 8 and were significantly suppressed on LD13 in the nafarelin group.
    3 context sentences
    Summary · context
    In 26 infertile women 50 mg clomiphene citrate produced a preovulatory-size follicle.
    Summary · context
    Then, 11 women were randomized to receive two 400-micrograms doses of nafarelin intranasally 16 h apart, and 15 women were injected intramuscularly with 5000 IU of hCG (luteal day 0 = LD0).
    Summary · context
    Starting on LD6, 7 more 400-micrograms doses of nafarelin were repeated on an every 16-h schedule or a single 2500 IU dose of hCG was given, respectively.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In infertile women primed with clomiphene, LH was significantly suppressed on LD13 with nafarelin compared with hCG.

    In plain wordsIn infertile women primed with clomiphene, LH was lower on LD13 with nafarelin than hCG.

    Peptide
    Nafarelin
    Outcome
    DecreaseLH on LD13
    Study

    n: not reported in source

    Comparator
    hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 micrograms per dose · intranasalAs given in this study (human).

    Source sentences

    Summary
    LH and FSH levels were significantly higher on LD1, 7, and 8 and were significantly suppressed on LD13 in the nafarelin group.
    3 context sentences
    Summary · context
    In 26 infertile women 50 mg clomiphene citrate produced a preovulatory-size follicle.
    Summary · context
    Then, 11 women were randomized to receive two 400-micrograms doses of nafarelin intranasally 16 h apart, and 15 women were injected intramuscularly with 5000 IU of hCG (luteal day 0 = LD0).
    Summary · context
    Starting on LD6, 7 more 400-micrograms doses of nafarelin were repeated on an every 16-h schedule or a single 2500 IU dose of hCG was given, respectively.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In infertile women primed with clomiphene, FSH was significantly suppressed on LD13 with nafarelin compared with hCG.

    In plain wordsIn infertile women primed with clomiphene, FSH was lower on LD13 with nafarelin than hCG.

    Peptide
    Nafarelin
    Outcome
    DecreaseFSH on LD13
    Study

    n: not reported in source

    Comparator
    hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 micrograms per dose · intranasalAs given in this study (human).

    Source sentences

    Summary
    LH and FSH levels were significantly higher on LD1, 7, and 8 and were significantly suppressed on LD13 in the nafarelin group.
    3 context sentences
    Summary · context
    In 26 infertile women 50 mg clomiphene citrate produced a preovulatory-size follicle.
    Summary · context
    Then, 11 women were randomized to receive two 400-micrograms doses of nafarelin intranasally 16 h apart, and 15 women were injected intramuscularly with 5000 IU of hCG (luteal day 0 = LD0).
    Summary · context
    Starting on LD6, 7 more 400-micrograms doses of nafarelin were repeated on an every 16-h schedule or a single 2500 IU dose of hCG was given, respectively.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In infertile women primed with clomiphene, luteal estradiol or progesterone levels differed significantly only on LD13, with lower values with nafarelin than hCG.

    In plain wordsIn infertile women given clomiphene, luteal estradiol or progesterone levels differed only on luteal day 13, with lower values on nafarelin than hCG.

    Peptide
    Nafarelin
    Outcome
    DecreaseLuteal estradiol or progesterone on LD13
    Study

    n: not reported in source

    Comparator
    hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 micrograms per dose · intranasalAs given in this study (human).

    Source sentences

    Summary
    Significantly different luteal E2 or P levels were noted only on LD13, with lower values in the nafarelin group.
    3 context sentences
    Summary · context
    In 26 infertile women 50 mg clomiphene citrate produced a preovulatory-size follicle.
    Summary · context
    Then, 11 women were randomized to receive two 400-micrograms doses of nafarelin intranasally 16 h apart, and 15 women were injected intramuscularly with 5000 IU of hCG (luteal day 0 = LD0).
    Summary · context
    Starting on LD6, 7 more 400-micrograms doses of nafarelin were repeated on an every 16-h schedule or a single 2500 IU dose of hCG was given, respectively.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In infertile women primed with clomiphene, luteal progesterone was significantly lower with nafarelin than hCG only on LD13.

    In plain wordsIn infertile women primed with clomiphene, progesterone was significantly lower with nafarelin than hCG only on LD13.

    Peptide
    Nafarelin
    Outcome
    DecreaseProgesterone on LD13
    Study

    n: not reported in source

    Comparator
    hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 micrograms per dose · intranasalAs given in this study (human).

    Source sentences

    Summary
    Significantly different luteal E2 or P levels were noted only on LD13, with lower values in the nafarelin group.
    3 context sentences
    Summary · context
    In 26 infertile women 50 mg clomiphene citrate produced a preovulatory-size follicle.
    Summary · context
    Then, 11 women were randomized to receive two 400-micrograms doses of nafarelin intranasally 16 h apart, and 15 women were injected intramuscularly with 5000 IU of hCG (luteal day 0 = LD0).
    Summary · context
    Starting on LD6, 7 more 400-micrograms doses of nafarelin were repeated on an every 16-h schedule or a single 2500 IU dose of hCG was given, respectively.
  10. 10HumanNon-randomized trialEfficacy outcome

    In infertile women primed with clomiphene, all nafarelin patients had mid-luteal progesterone above 10 ng/ml, as did hCG patients.

    In plain wordsIn infertile women primed with clomiphene, mid-luteal progesterone exceeded 10 ng/ml in all nafarelin patients, as in hCG patients.

    Peptide
    Nafarelin
    Outcome
    Not applicableMid-luteal progesterone
    Study

    n = 11

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 micrograms per dose · intranasalAs given in this study (human).

    Measurements

    Mid-luteal progesterone
    > 10 ng/ml
    all patients

    Source sentences

    Summary
    All patients had mid-luteal P levels greater than 10 ng/ml and luteal phases longer than 13 days.
    3 context sentences
    Summary · context
    In 26 infertile women 50 mg clomiphene citrate produced a preovulatory-size follicle.
    Summary · context
    Then, 11 women were randomized to receive two 400-micrograms doses of nafarelin intranasally 16 h apart, and 15 women were injected intramuscularly with 5000 IU of hCG (luteal day 0 = LD0).
    Summary · context
    Starting on LD6, 7 more 400-micrograms doses of nafarelin were repeated on an every 16-h schedule or a single 2500 IU dose of hCG was given, respectively.
  11. 11HumanNon-randomized trialEfficacy outcome

    In infertile women primed with clomiphene, all nafarelin patients had luteal phases longer than 13 days, as did hCG patients.

    In plain wordsIn infertile women primed with clomiphene, luteal phases exceeded 13 days in all nafarelin patients, as in hCG patients.

    Peptide
    Nafarelin
    Outcome
    Not applicableLuteal phase length
    Study

    n = 11

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 micrograms per dose · intranasalAs given in this study (human).

    Measurements

    Luteal phase length
    > 13 days
    all patients

    Source sentences

    Summary
    All patients had mid-luteal P levels greater than 10 ng/ml and luteal phases longer than 13 days.
    3 context sentences
    Summary · context
    In 26 infertile women 50 mg clomiphene citrate produced a preovulatory-size follicle.
    Summary · context
    Then, 11 women were randomized to receive two 400-micrograms doses of nafarelin intranasally 16 h apart, and 15 women were injected intramuscularly with 5000 IU of hCG (luteal day 0 = LD0).
    Summary · context
    Starting on LD6, 7 more 400-micrograms doses of nafarelin were repeated on an every 16-h schedule or a single 2500 IU dose of hCG was given, respectively.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.